Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IGMS

IGM Biosciences (IGMS) Stock Price, News & Analysis

IGM Biosciences logo

About IGM Biosciences Stock (NASDAQ:IGMS)

Key Stats

Today's Range
$1.27
$1.27
50-Day Range
$1.26
$1.36
52-Week Range
$0.92
$22.50
Volume
N/A
Average Volume
480,746 shs
Market Capitalization
$76.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.89
Consensus Rating
Reduce

Company Overview

IGM Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

IGMS MarketRank™: 

IGM Biosciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 516th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IGM Biosciences has received a consensus rating of Reduce. The company's average rating score is 1.89, and is based on no buy ratings, 8 hold ratings, and 1 sell rating.

  • Upside Potential

    IGM Biosciences has a consensus price target of $4.89, representing about 285.0% upside from its current price of $1.27.

  • Amount of Analyst Coverage

    IGM Biosciences has received no research coverage in the past 90 days.

  • Read more about IGM Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for IGM Biosciences are expected to grow in the coming year, from ($3.35) to ($0.96) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IGM Biosciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IGM Biosciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    IGM Biosciences has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about IGM Biosciences' valuation and earnings.
  • Short Interest

    There is no current short interest data available for IGMS.
  • Dividend Yield

    IGM Biosciences does not currently pay a dividend.

  • Dividend Growth

    IGM Biosciences does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for IGMS.
  • Search Interest

    5 people have searched for IGMS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IGM Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,117.00 in company stock.

  • Percentage Held by Insiders

    57.00% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.79% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IGM Biosciences' insider trading history.
Receive IGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IGMS Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
See More Headlines

IGMS Stock Analysis - Frequently Asked Questions

IGM Biosciences, Inc. (NASDAQ:IGMS) posted its quarterly earnings data on Thursday, July, 31st. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of ($0.30) by $1.88. The firm had revenue of $143.62 million for the quarter, compared to analysts' expectations of $3.20 million. IGM Biosciences had a negative trailing twelve-month return on equity of 93.35% and a negative net margin of 36.81%.

IGM Biosciences (IGMS) raised $125 million in an initial public offering (IPO) on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Top institutional shareholders of IGM Biosciences include Geode Capital Management LLC (0.35%), Jane Street Group LLC (0.30%), Marshall Wace LLP (0.07%) and XTX Topco Ltd (0.04%). Insiders that own company stock include Bros Advisors Lp Baker, Mary Beth Harler, Fred Schwarzer, Misbah Tahir, Bruce Keyt, Jakob Haldor Topsoe, Lisa Lynn Decker, Chris H Takimoto, George Gauthier, Michael D Loberg, Steven Weber and Julie Hambleton.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that IGM Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
7/31/2025
Today
9/17/2025
Next Earnings (Estimated)
11/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IGMS
CIK
1496323
Fax
N/A
Employees
190
Year Founded
2010

Price Target and Rating

High Price Target
$20.00
Low Price Target
$1.50
Potential Upside/Downside
+285.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$195.79 million
Net Margins
-36.81%
Pretax Margin
-36.81%
Return on Equity
-93.35%
Return on Assets
-24.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
17.66
Quick Ratio
17.66

Sales & Book Value

Annual Sales
$145.05 million
Price / Sales
0.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.67 per share
Price / Book
0.76

Miscellaneous

Outstanding Shares
60,293,000
Free Float
25,926,000
Market Cap
$76.57 million
Optionable
Optionable
Beta
0.60

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:IGMS) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners